Johnson & Johnson has announced its pharmaceutical business segment Janssen will adopt the Johnson & Johnson brand name in Ireland

Johnson & Johnson is a name that has been synonymous with healthcare for almost a century in Ireland. The company has been at the forefront of innovation in medicine and medical technology, and its operations in Ireland have played a significant role in the company’s global success.

The company has announced that its pharmaceutical business segment, Janssen, will adopt the Johnson & Johnson brand name in Ireland. Janssen will become Johnson & Johnson Innovative Medicine, and the medical technology segment will continue to be named Johnson & Johnson MedTech.

This move marks the next era for Johnson & Johnson in Ireland, leveraging its expertise in innovative medicine and medical technology to prevent and treat complex diseases and introduce solutions that are smarter, less invasive, and more personalised.

Operating in Ireland since 1935, Johnson & Johnson has a long heritage and a large footprint here with a workforce of over 6,000 people. Its Irish operations which comprise both the Innovative Medicine and MedTech segments, make a significant contribution to the company’s global success with ten sites located in five counties (Cork, Dublin, Limerick, Galway and Mayo) spanning research and development, manufacturing, shared services and country commercial businesses.

It’s chocs away, with a magical escape from the ordinary on the westernmost side of Dingle’s Slea Head

---

The Irish-owned vehicle leasing company beating global giants

---

Why recognition of prior learning works for business

---

In an era of hybrid working, how do businesses unify communications securely?

---

Johnson & Johnson Innovative Medicine innovates with the goal of leading where medicine is going. Its ambition is to tackle the toughest health challenges, where patient need is highest. Currently, its research and development is focused on the areas of oncology, immunology, neuroscience, cardiopulmonary and specialty ophthalmology, with a commitment to changing the standard of care including evaluation of new drugs and therapeutic interventions that are personalised for optimised clinical outcomes.

Personalised care is about going beyond a one-size-fits-all approach to medicine that leverages deep scientific knowledge and advances in technology to better understand the drivers of disease and develop targeted medicines for specific sub-sets of patients. The company does this in its own labs but also in collaboration with its partners to match the right patients to the right targeted medicines at the right time, depending on the specific biology of their disease.

Data is also helping to drive innovation at Johnson & Johnson. Scientific data, when applied through advanced technologies such as AI, is enabling the recognition of never-before-seen patterns in health. This enables greater understanding of unique health challenges to develop innovations that meet patients’ needs more quickly.

Patients ultimately inform and inspire the company’s innovations and are at the heart of everything they do. They are represented in all aspects of research, development, and delivery, ensuring their perspectives are included to improve their treatment experience and outcome. Research and development are at the core of how the company evolves.

Here in Ireland, the Johnson & Johnson Innovative Medicine facility in Ringaskiddy in Cork, is contributing to this work through the provision of end-to-end development and manufacturing support to the global biotherapeutics portfolio. The team at another facility located in Little Island in Cork, manufactures bulk active pharmaceutical ingredients that are exported around the world to be further processed into tablets, creams or injectable medicines. The team in Dublin act as the commercial arm of the business and ensures patients in Ireland have access to its medicines. Between 2012 and 2023, the company brought 14 new medicines to patients in Ireland and currently supports 9 clinical trials for new medicines.

The company also collaborates with the wider healthcare system including patient support groups, to help empower patients through education, new programmes, and tools to better help them navigate their journey and manage their disease.

Fuelled by innovation at the intersection of biology and technology, Johnson & Johnson MedTech is developing the next generation of smarter, less invasive and more personalised treatments.

Johnson & Johnson MedTech Orthopaedics in Cork provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement for millions of patients. Johnson & Johnson MedTech Vision in Limerick is re-imagining the future of eye health and delivering an all-encompassing portfolio of solutions to transform patients’ lives. Cerenovus in Galway, an emerging leader in neurovascular care and part of Johnson & Johnson MedTech, is a world-leading research site for stroke, collaborating with physicians globally to develop innovative devices that improve clinical outcomes for stroke patients.

With a renewed focus on innovative medicine and medical technology, Johnson & Johnson is poised to continue leading the way in healthcare and making a real difference in the lives of patients.

There will be no change to the company names and/or legal status of Johnson & Johnson Innovative Medicine or MedTech companies in Ireland. Johnson & Johnson Innovative Medicine companies are Janssen Sciences Ireland UC and Janssen Pharmaceutical Sciences UC.

References available on request.